Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2025 02:00 ET | Source: Avextra Pharma GmbH

Avextra Unveils Promising Study Results at Major Pain Congress

New Data Highlights Superior Efficacy and Tolerability of Avextra 10/10 in Treating Chemotherapy-Induced Neuropathic Pain News Release Bensheim, Germany – 13 March 2025 – At its annual congress in...
March 06, 2025 01:00 ET | Source: Avextra Pharma GmbH

Avextra erweitert Produktportfolio an Cannabis-basierten Arzneimitteln

Zu den Deutschen Schmerz- und Palliativtagen erweitert Avextra sein Produktportfolio um einen 25/25 Cannabisextrakt und stellt erste Studienergebnisse vor Avextra erweitert sein...
December 20, 2024 12:00 ET | Source: Avextra Pharma GmbH

Avextra Backs Landmark Psilocybin Therapy Study in Palliative Care

News Release Exclusive Industry Role: Avextra is the industry partner in a groundbreaking project focused on psychedelic-assisted therapy for patients in palliative care suffering from...
December 12, 2024 07:00 ET | Source: Avextra Pharma GmbH

Psypal - Neue Hoffnung für Patient:innen dank EU Förderung

BENSHEIM, Deutschland, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Die erste vollständig von der EU finanzierte Psilocibin-Therapiestudie, hat nun die Zulassung der Europäischen Arzneimittel-Behörde EMA...
December 12, 2024 07:00 ET | Source: Avextra Pharma GmbH

Avextra Supports First Fully EU-Funded Psilocybin Therapy Study, Now Approved by EMA

Exclusive Industry Role: Avextra is the industry partner in the first EU-funded project focused on psychedelic-assisted therapy for patients in palliative care suffering from depression, with a total...
November 20, 2024 07:00 ET | Source: Avextra AG

Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar

Avextra Portugal launches an innovative in-house breeding program to develop proprietary cannabis varieties with specific, consistent and reproducible cannabinoid and terpene profiles.Over a two-year...
October 08, 2024 07:00 ET | Source: Avextra AG

Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases

The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS; a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra oral...
October 08, 2024 07:00 ET | Source: Avextra AG

Avextra annuncia l’approvazione da parte dell'Agenzia Italiana del Farmaco (AIFA) di NEUROBIS uno studio clinico di Fase II che utilizza estratto di cannabis AVEXTRA per il trattamento delle malattie neurodegenerative

L'Agenzia Italiana del Farmaco (AIFA) e il Ministero della Salute hanno approvato ufficialmente NEUROBIS: uno studio multicentrico di Fase II per valutare la sicurezza e l'efficacia di una...
June 20, 2024 01:00 ET | Source: Avextra AG

Avextra und SynQube GmbH geben eine strategische Partnerschaft in der Arzneimittelentwicklung mit Cannabinoiden und anderen psychotropen Substanzen bekannt

Avextra, der führende europäische vertikal integrierte Hersteller und Entwickler von Medikamenten auf Cannabisbasis, erweitert nach Abschluss seiner Finanzierungsrunde im ersten Quartal 2024 seine...
June 20, 2024 01:00 ET | Source: Avextra AG

Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development with Cannabinoids and other Psychotropic Substances

Avextra, the leading European vertically-integrated manufacturer and developer of cannabis-based medicines is expanding its pharmaceutical development capabilities. Behind SynQube GmbH are the two...